HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Tuberculosis infection following anti-TNF therapy in inflammatory bowel disease, despite negative screening.

Abstract
We present two patients with inflammatory bowel disease who, despite negative tuberculosis screening, developed a de novo tuberculosis infection after the start of anti tumor necrosis factor alpha treatment. We discuss current screening methods and their limitations, the approach after positive screening and the timing to resume anti-TNF╬▒ treatment after TB infection. We shortly mention the immune reconstitution inflammatory syndrome (IRIS), described in a few cases after the stop of anti-TNFalpha while treating the tuberculosis infection. We conclude with some remaining questions concerning tuberculosis in IBD patients.
AuthorsCeline Debeuckelaere, Paul De Munter, Pascal Van Bleyenbergh, Walter De Wever, Gert Van Assche, Paul Rutgeerts, Severine Vermeire
JournalJournal of Crohn's & colitis (J Crohns Colitis) Vol. 8 Issue 6 Pg. 550-7 (Jun 2014) ISSN: 1876-4479 [Electronic] Netherlands
PMID24295645 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright © 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
  • Tumor Necrosis Factor-alpha
  • Infliximab
Topics
  • Adult
  • Antibodies, Monoclonal (adverse effects, therapeutic use)
  • Colitis, Ulcerative (complications, drug therapy)
  • Crohn Disease (complications, drug therapy)
  • False Negative Reactions
  • Humans
  • Infliximab
  • Male
  • Middle Aged
  • Tuberculosis, Pulmonary (chemically induced, diagnosis, etiology)
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: